My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.46 +0.09 (+0.49%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce ↗

January 24, 2023

Via Benzinga

Current Report: Takeda Pharmaceutical (TAK) ↗

January 23, 2023

In the past year, Takeda’s share price increased by $1.73, or about 12%.

Via Talk Markets

HUTCHMED Out Licenses Fruquintinib To Takeda Outside China ↗

January 23, 2023

Via Benzinga

Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices ↗

January 14, 2023

Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...

Via Talk Markets

Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study ↗

January 09, 2023

Via Benzinga

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

A Bullish Sign Appears On Takeda Pharmaceutical's Chart ↗

December 28, 2022

Via Benzinga

Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B ↗

December 13, 2022

Via Benzinga

Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗

November 23, 2022

Via Benzinga

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗

December 14, 2022

Via Benzinga

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? ↗

November 30, 2022

Tech layoffs are in the news, but life sciences companies seem to be doing better.

Via The Motley Fool

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease ↗

November 29, 2022

The company says it plans soon to present Phase 2 results and its Phase 3 study design.

Via Investor's Business Daily

Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved ↗

November 22, 2022

This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...

Via Benzinga

Takeda Posts Lower 1H Profit, Lifts FY22 Outlook ↗

October 27, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids ↗

October 05, 2022

Via Benzinga

Why Puma Biotechnology's Shares Jumped 20% on Monday ↗

November 21, 2022

It may have benefited from positive news about another company's drug candidate.

Via The Motley Fool

Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗

November 17, 2022

Via Benzinga

2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade ↗

November 16, 2022

Is now the time to load up on these high-yielding investments?

Via The Motley Fool

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗

November 02, 2022

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

Via The Motley Fool

7 Dividend Stocks to Sell Pronto Before a Painful Downturn ↗

October 24, 2022

Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.

Via InvestorPlace

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

3 High-Yielding Dividend Stocks Near Their 52-Week Lows ↗

October 19, 2022

These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.

Via The Motley Fool

Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer ↗

September 21, 2022

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

7 Stocks Under $15 to Buy and Hold Forever ↗

September 01, 2022

For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.

Via InvestorPlace

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 30, 2022

Via Benzinga

Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate ↗

August 30, 2022

The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.